Company introduction

서브배너

Greetings from the CEO

“A company that constantly
challenges
for a prosperous and
healthy life for mankind”
Renhaim Inc. is a dynamically evolving biotechnology company committed to
enhancing the promotion of robust and thriving human life through advancements
in genomic technology, particularly the mRNA platform.

Our company thrives on a youthful and vibrant business culture,
effectively implementing developmental initiatives grounded in open communication,
freedom, and equality.

With unwavering dedication, we are determined to realize our vision of becoming a global leader
in healthcare, harnessing unique technologies and strategic developmental approaches.

Kang, Taejin CEO of
Renhain Inc.

Scientific Advisory Board

김항래
Kim, Hang-rae
  • Technical Advisor of Renhaim Inc.
  • Professor, Department of Medicine,
    Seoul National University School of Medicine
  • a visiting professor at Yale University School of Medicine
  • Yale University School of Medicine, Post-Doc
  • Bionia, Senior Researcher
  • Doctor of Microbiology and Immunology,
    Seoul National University School of Medicine
Larry Kwak
Larry Kwak
  • Technical Advisor of Renhaim Inc.
  • Vice President and Deputy Director, City of Hope
  • Winner of Ho-Am Prize in Medicine in 2016
  • Time’s list of most influential 100 people in 2010
  • Master of Cancer Vaccine
신현무
Shin, Hyun-moo
  • Associate Professor, Department of Medicine,
    Seoul National University College of Medicine
  • Univ. of Massachusetts medical School, Post-Doc
  • Univ. of Massachusetts, Amherst, doctor of science
이창한
Lee, Chang-han
  • Assistant Professor, Department of Medicine,
    Seoul National University College of Medicine
  • Univ. of Texas at Austin, Research associate
  • Univ. of Texas at Austin, Post-Doc research fellow
  • Doctor of Molecular Science and Engineering, Ajou University